A total of 59.8% (73/122) of the tumor samples in which ASPP2 had high expression, showed low expression of BECN1, whereas high expression of BECN1 was found in about 67.2% (43/64) of tumor samples in which ASPP2 was low expression. This evidence concerns the gene TP53BP2 and neoplasm.